Clinical Trials · NCT07645326
RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Georgetown University
- Enrollment
- 108
- Start date
- Dec 2026
- Locations
- 1 site, United States
- Primary endpoint
- Radiological progression-free survival (rPFS)